News | Advanced Visualization | October 29, 2019

Vida Partners With TeraRecon for Distribution of AI-powered Lung Analysis

LungPrint Discovery offers fully automatic radiological metrics and unique, time-saving airway visualizations

LungPrint Discovery offers fully automatic radiological metrics and unique, time-saving airway visualizations

October 29, 2019 — VIDA Diagnostics, Inc. announced that its LungPrint analysis will be available through TeraRecon’s AI Interoperability platform, EnvoyAI, expanding the reach of VIDA’s leading AI-powered pulmonary care solutions and creating an integrated physician experience. 

LungPrint Discovery offers fully automatic radiological metrics and unique, time-saving airway visualizations. By precisely quantifying lung characteristics in a chest CT scan, LungPrint helps providers detect COPD and other interstitial lung disease earlier, often when debilitating symptoms have yet to occur. Early detection of chronic lung disease is reported to elongate life expectancies and reduce overall healthcare costs (Larsson, et. al). LungPrint also strengthens collaboration between radiologists and pulmonary clinicians, enhancing the content delivered in radiology reports and care team collaboration 

“VIDA is a valuable addition to our partner eco-system, offering physicians premium lung analysis and characterization AI with an integrated user experience that can only be achieved when interoperability is prioritized,” said Jeff Sorenson, chief executive officer and president of TeraRecon. “Our customers have come to expect clinical workflow excellence for optimal patient care, and VIDA’s LungPrint solution brings another best-in-class application to our wide portfolio of AI algorithms available directly within our customers’ interpretation workflow.” 

“VIDA and TeraRecon have a shared goal of equipping care teams with cutting-edge, clinically validated AI solutions,” said Susan A. Wood, Ph.D., CEO of VIDA. “We are excited to be partnering with TeraRecon; their AI platform elegantly integrates novel AI solutions like ours into the radiology workflow, which is a critical requirement in driving broad AI adoption in healthcare.” 

LungPrint is an AI-powered imaging suite advancing pulmonary care by uniquely profiling the patient with or at risk of lung diseases, including interstitial lung diseases and COPD, which continue to be under-diagnosed. The solution grants providers access to important insights to better understand their patients’ set of conditions and to select the best care path to match those unique conditions. 

By supporting earlier recognition, LungPrint aims to improve health outcomes, quality of care and the patient experience, while reducing overall healthcare costs. Learn more about LungPrint and how it enables radiology to help physicians catch COPD early, improving quality of care, patient outcomes and the cost of healthcare delivery. 

For more information: www.vidalung.ai

Related Content

In the light of the coronavirus outbreak, MILabs has enhanced its line of high-performance CT scanners to even better detect the disease #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Computed Tomography (CT) | March 27, 2020
March 27, 2020 — Based on recent scientific research, diagnostic X-ray...
CoronaCare is designed to help healthcare providers track COVID-19 (coronavirus) related symptoms of potentially infected patients. The platform enables communication with patients outside of facility walls and the ability to request the return of high-risk patients for more in-depth care. #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Coronavirus (COVID-19) | March 27, 2020
March 27, 2020 — PaxeraHealth has spent years building and be
AI vendor Infervision's InferRead CT Pneumonia software uses artificial intelligence-assisted diagnosis to improve the overall efficiency of the radiology department. It is being developed in China as a high sensitivity detection aid for novel coronavirus pneumonia (COVID-19). #COVID19 #coronavirus #SARScov2

AI vendor Infervision's InferRead CT Pneumonia software uses artificial intelligence-assisted diagnosis to improve the overall efficiency of the radiology department. It is being developed in China as a high sensitivity detection aid for novel coronavirus pneumonia (COVID-19).

Feature | Coronavirus (COVID-19) | March 27, 2020 | Jilian Liu, M.D., HIMSS Greater China
An older couple walked into the Hubei Provincial Hospital of Integrated Chinese and Western Medicine near their neigh
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Typical CT imaging features for COVID-19. Unenhanced, thin-section axial images of the lungs in a 52-year-old man with a positive RT-PCR (A-D) show bilateral, multifocal rounded (asterisks) and peripheral GGO (arrows) with superimposed interlobular septal thickening and visible intralobular lines (“crazy-paving”). Routine screening CT for diagnosis or exclusion of COVID-19 is currently not recommended by most professional organizations or the US Centers for Disease Control and Prevention. Image courtesy of RSNA

News | Coronavirus (COVID-19) | March 26, 2020
March 26, 2020 — The Radiological Society of North America (RSNA
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Artificial Intelligence | March 24, 2020
March 24, 2020 — Qure.ai, a leading healthcare...